Virax Biolabs Group Ltd SEC filings VRAX
Virax Biolabs Group Ltd has 159 filings in SEC EDGAR's recent list, going back to Dec 27, 2021. Its latest annual report, Form 20-F, was filed on Jul 6, 2026 for the period ended Mar 31, 2026. The most recent current report (Form 6-K) was filed on Oct 29, 2026. The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 3, 2026 | — |
| EFFECT | Filing | Dec 30, 2025 | — |
| CORRESP | Letter to the SEC | Dec 29, 2025 | — |
| D | Filing | Dec 18, 2025 | — |
| NT 20-F | Filing | Aug 1, 2024 | Jul 31, 2024 |
| EFFECT | Filing | Dec 15, 2023 | — |
| CORRESP | Letter to the SEC | Dec 13, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 12, 2023 | — |
| D | Filing | Oct 17, 2023 | — |
| EFFECT | Filing | Mar 30, 2023 | — |
| CORRESP | Letter to the SEC | Mar 28, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 28, 2023 | — |
| D | Filing | Mar 15, 2023 | — |
| EFFECT | Filing | Dec 1, 2022 | — |
| CORRESP | Letter to the SEC | Nov 29, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 25, 2022 | — |
| NT 20-F | Filing | Jul 29, 2022 | Mar 31, 2022 |
| CERT | Filing | Jul 20, 2022 | — |
| EFFECT | Filing | Jun 30, 2022 | — |
| 8-A12B | For registration of certain classes | Jun 30, 2022 | — |
| CORRESP | Letter to the SEC | Jun 28, 2022 | — |
| CORRESP | Letter to the SEC | Jun 28, 2022 | — |
| CORRESP | Letter to the SEC | Jun 24, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 24, 2022 | — |
| CORRESP | Letter to the SEC | Jun 24, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 23, 2022 | — |
| CORRESP | Letter to the SEC | Jun 21, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 16, 2022 | — |
| CORRESP | Letter to the SEC | May 11, 2022 | — |
| UPLOAD | Letter from the SEC | May 5, 2022 | — |
| CORRESP | Letter to the SEC | Apr 22, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 7, 2022 | — |
| CORRESP | Letter to the SEC | Mar 18, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 10, 2022 | — |
| DRSLTR | Filing | Feb 17, 2022 | — |
| DRS/A | Filing | Feb 17, 2022 | — |
| UPLOAD | Letter from the SEC | Jan 28, 2022 | — |
| DRS | Filing | Dec 27, 2021 | — |
Showing 38 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- VRAX (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Cayman Islands
- Headquarters
- Lanarkshire, United Kingdom
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1885827
- Former names
- Virax Biolabs (Cayman) Ltd (until Dec 27, 2021)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.